PwC expects the pharmaceutical supply chain to be remodeled in the coming years and result in the creation of various models that fit particular warehouse supplies, products and patient groups. The supply chain will be a significant metric in differentiating among various pharmaceutical companies and will also become a two-way information portal.
“The most successful [pharmaceutical] companies will be those that recognize the underlying value locked in their supply chain and can leverage it as a value and brand differentiator rather than just a cost,” said Steve Arlington, PwC’s global advisory pharmaceutical and life sciences leader. “Companies that recognize information is the currency of the future, will be those that go the final mile and stand out by 2020.”